Whole-genome sequencing of cell-free DNA for assessment of minimal residual disease in high-risk smoldering multiple myeloma
A simple blood test using whole-genome sequencing detects early myeloma without bone marrow biopsy, enabling closer monitoring of high-risk patients.
This study validates whole-genome sequencing of circulating cell-free DNA as a method for assessing minimal residual disease in high-risk smoldering multiple myeloma. It demonstrates a non-invasive liquid biopsy approach that could enable earlier intervention and disease monitoring in the precursor myeloma stage.
What the study was
- Study design
- Validation study
- Population
- High-risk smoldering multiple myeloma patients
- Category
- Early Detection
- Maturity
- Validated
- Journal
- HemaSphere
Why it surfaced
WGS-based cfDNA MRD in smoldering MM directly addresses the critical clinical need to monitor pre-malignant myeloma and time interventions; published in HemaSphere, a leading hematology journal.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.